KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Working Capital Changes (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Other Working Capital Changes for 8 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 115.0% year-over-year to $4.1 million, compared with a TTM value of $26.0 million through Dec 2025, up 253.75%, and an annual FY2025 reading of $26.0 million, up 253.75% over the prior year.
  • Other Working Capital Changes was $4.1 million for Q4 2025 at Esperion Therapeutics, down from $6.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $19.7 million in Q2 2025 and bottomed at -$27.1 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is $305950.0, with a median of $887500.0 recorded in 2021.
  • The sharpest move saw Other Working Capital Changes surged 1979.07% in 2021, then crashed 7830.51% in 2023.
  • Year by year, Other Working Capital Changes stood at $5.8 million in 2021, then crashed by 109.01% to -$518000.0 in 2022, then crashed by 794.98% to -$4.6 million in 2023, then crashed by 484.47% to -$27.1 million in 2024, then skyrocketed by 115.0% to $4.1 million in 2025.
  • Business Quant data shows Other Working Capital Changes for ESPR at $4.1 million in Q4 2025, $6.2 million in Q3 2025, and $19.7 million in Q2 2025.